Global Gastrointestinal Therapeutics Market 2016-2020

Publisher Name :
Date: 30-Sep-2016
No. of pages: 102
Inquire Before Buying

About Gastrointestinal Disorders

Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn's disease, ulcerative colitis, and peptic ulcers.

This analyst forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

The report, Global Gastrointestinal Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

AbbVie

Johnson & Johnson

Takeda

Allergan

UCB

Other prominent vendors

4SC

Ajinomoto Pharmaceuticals

Alfa Wassermann

Alizyme

Amgen

Anterogen

Ardelyx

Arena Pharmaceuticals

Astellas

AstraZeneca

Astellas Pharma

Avaxia Biologics

Biogen Idec

BioLineRx

Celgene

ChemoCentryx

Cosmo Pharmaceuticals

Drais Pharmaceuticals

Eisai

Eli Lilly

Enlivex Therapeutics

F. Hoffmann-La Roche

Ferring Pharmaceuticals

FF Pharma

Galapagos

Gilead Sciences

GlaxoSmithKline

Hutchison Medi Pharma

Immune Pharmaceuticals

InDex Pharmaceuticals

Ironwood Pharmaceuticals

Kaken Pharmaceutical

Kang Stem Biotech

Kissei Pharmaceutical

Kyowa Hakko Kirin

Lexicon Pharmaceuticals

Lipid Therapeutics

Meda

Merck

Mesoblast

Mitsubishi Tanabe

Mochida Pharmaceutical

Morphotek

Neovacs

Nestle

Norgine

Novartis

Ono Pharmaceutical

Pfizer

Procter & Gamble

Qu Biologics

Receptos

RedHill Biopharma

Salix Pharmaceuticals

Shield Therapeutics

Sterna Biologicals

Synergy Pharmaceuticals

Synthetic Biologics

TiGenix

Tillotts Pharma

TopiVert

TSD Japan

Zeria Pharmaceutical

Market driver

Tentative approval of late stage molecules

For a full, detailed list, view our report

Market challenge

Discontinuation of drugs under development and from the market

For a full, detailed list, view our report

Market trend

Emergence of biosimilars

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Global Gastrointestinal Therapeutics Market 2016-2020

Table of Contents

PART 01:Executive summary
Highlights
PART 02:Scope of the report
Market overview
Top-vendor offerings
PART 03:Market research methodology
Research methodology
Economic indicators
PART 04:Introduction
Key market highlights
PART 05:Pipeline portfolio
Ulcerative colitis
Crohn's disease
IBS
PART 06:Market landscape
Global gastrointestinal therapeutics market
PART 07:Market segmentation by disease type
Overview
PART 08:Global IBD therapeutics market
Global ulcerative colitis drugs market
Global Crohn's disease drugs market
Market segmentation by molecule type
PART 09:Global IBS therapeutics market
PART 10:Global gastrointestinal OTC drugs market
PART 11:Geographical segmentation
Global gastrointestinal therapeutics market by geography 2015-2020
Gastrointestinal therapeutics market in Americas
Gastrointestinal therapeutics market in EMEA
Gastrointestinal therapeutics market in APAC
PART 12:Market drivers
Increasing consumption of biologics
Tentative approval of late stage molecules
Development of novel therapies using innovative technologies
Improved diagnostic tools increasing the treatment-seeking population
PART 13:Impact of drivers
PART 14:Market challenges
Increased consumption of OTC medications
Unknown etiology of IBD and IBS
Discontinuation of drugs under development and from the market
PART 15:Impact of drivers and challenges
PART 16:Market trends
Patient assistance programs
Emergence of biosimilars
Rise in self-medication
Focus on regenerative medicines
Strategic alliances and M&A
PART 17:Vendor landscape
Competitive scenario
Other prominent vendors
PART 18:Key vendor analysis
AbbVie
Johnson & Johnson
Takeda
Allergan
UCB
PART 19:Appendix
List of abbreviations

List of Exhibits

Exhibit 01:Product offerings
Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015
Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments
Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio
Exhibit 05:Global Crohn's disease therapeutics market: Pipeline portfolio
Exhibit 06:Global IBS therapeutics market: Pipeline portfolio
Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
Exhibit 09:Approval and patent expiries of top selling biologics
Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions)
Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
Exhibit 12:Five forces analysis
Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015
Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020
Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015
Exhibit 17:Global IBD therapeutics market by type 2015-2020
Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis
Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 20:Global Crohn's disease drugs market 2015-2020 ($ billions)
Exhibit 21:Global IBD therapeutics market by molecule type 2015
Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions)
Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US
Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020
Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020
Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015
Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015
Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas
Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA
Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC
Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market
Exhibit 41:Biologics for IBD: market share 2012-2022
Exhibit 42:Few biologics under development for gastrointestinal disorders
Exhibit 43:Impact of drivers
Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors
Exhibit 45:Gastrointestinal therapeutics discontinued from development or market
Exhibit 46:Impact of drivers and challenges
Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends
Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US
Exhibit 49:Biosimilars under development for gastrointestinal disorders
Exhibit 50:Regenerative medicines for IBD under development
Exhibit 51:Key vendors ranking 2015
Exhibit 52:Key vendors: Geographical presence
Exhibit 53:Market vendors: Competitive scenario 2015-2020
Exhibit 54:AbbVie: Profile
Exhibit 55:AbbVie: Strength analysis
Exhibit 56:AbbVie: Growth strategy matrix
Exhibit 57:AbbVie: Opportunity assessment
Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
Exhibit 59:Johnson & Johnson: Profile
Exhibit 60:Johnson & Johnson: Strength analysis
Exhibit 61:Johnson & Johnson: Growth strategy matrix
Exhibit 62:Johnson & Johnson: Opportunity assessment
Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 65:Takeda: Profile
Exhibit 66:Takeda: Strength analysis
Exhibit 67:Takeda: Growth strategy matrix
Exhibit 68:Takeda: Opportunity assessment
Exhibit 69:Allergan: Profile
Exhibit 70:Allergan: Strength analysis
Exhibit 71:Allergan: Growth strategy matrix
Exhibit 72:Allergan: Opportunity assessment
Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
Exhibit 74:UCB: Profile
Exhibit 75:UCB: Strength analysis
Exhibit 76:UCB: Growth strategy matrix
Exhibit 77:UCB: Opportunity assessment
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • United States Esomeprazole Market Report 2017
    Published: 13-Jan-2017        Price: US 3800 Onwards        Pages: 114
    Notes: Sales, means the sales volume of Esomeprazole Revenue, means the sales value of Esomeprazole This report studies sales (consumption) of Esomeprazole in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AstraZeneca AB - Sandoz - Actavis - Teva - Mylan - KernPharm - Garmish Pharmaceuticals - Sanofi - Mepha - Saval Pharmace......
  • Global Esomeprazole Sales Market Report 2017
    Published: 12-Jan-2017        Price: US 4000 Onwards        Pages: 112
    Notes: Sales, means the sales volume of Esomeprazole Revenue, means the sales value of Esomeprazole This report studies sales (consumption) of Esomeprazole in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - AstraZeneca AB - Sandoz - Actavis - Teva - Mylan - KernPharm......
  • China Esomeprazole Market Research Report 2017
    Published: 11-Jan-2017        Price: US 3200 Onwards        Pages: 111
    Notes: Sales, means the sales volume of Esomeprazole Revenue, means the sales value of Esomeprazole This report studies Esomeprazole in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - AstraZeneca AB - Sandoz - Actavis - Teva - Mylan - KernPharm - Garmish Pharmaceuticals - Sanofi - Mepha - Saval Ph......
  • Duodenal Ulcer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Duodenal Ulcer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Duodenal Ulcer Report is to understand the market and pipeline status of the drugs around the Duodenal Ulcer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on desi......
  • Mezavant Xl -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Mezavant Xl- Drug Insights, 2017" highlights the Mezavant Xl marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Mezavant Xl covering the total sales estimation and also provides the Mezavant Xl sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Mezavant Xl, patents in......
  • Mucosta -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Mucosta- Drug Insights, 2017" highlights the Mucosta marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Mucosta covering the total sales estimation and also provides the Mucosta sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Mucosta, patents information and exclus......
  • Gastric Ulcers-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Gastric Ulcers-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Gastric Ulcers Report is to understand the market and pipeline status of the drugs around the Gastric Ulcers to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on desi......
  • Peptic Ulcer  - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Peptic Ulcer - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Peptic Ulcer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Peptic Ulcer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Peptic Ulc......
  • Irritable Bowel Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Irritable Bowel Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Irritable Bowel Syndrome Report is to understand the market and pipeline status of the drugs around the Irritable Bowel Syndrome to explore the generic development opportunities, licensing opportunities and to gain......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs